Cocrystal Pharma COCP Stock
Cocrystal Pharma Price Chart
Cocrystal Pharma COCP Financial and Trading Overview
| Cocrystal Pharma stock price | 1.42 USD |
| Previous Close | 2.55 USD |
| Open | 2.62 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 3000 |
| Day's Range | 2.52 - 2.72 USD |
| 52 Week Range | 1.74 - 6.24 USD |
| Volume | 58.68K USD |
| Avg. Volume | 72.73K USD |
| Market Cap | 26.55M USD |
| Beta (5Y Monthly) | 1.18508 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.72 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.67 USD |
COCP Valuation Measures
| Enterprise Value | -8006311 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.0829874 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.6131078 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.425 |
Trading Information
Cocrystal Pharma Stock Price History
| Beta (5Y Monthly) | 1.18508 |
| 52-Week Change | -44.23% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 6.24 USD |
| 52 Week Low | 1.74 USD |
| 50-Day Moving Average | 2.45 USD |
| 200-Day Moving Average | 2.6 USD |
COCP Share Statistics
| Avg. Volume (3 month) | 72.73K USD |
| Avg. Daily Volume (10-Days) | 40.75K USD |
| Shares Outstanding | 10.17M |
| Float | 7.12M |
| Short Ratio | 0.65 |
| % Held by Insiders | 25.04% |
| % Held by Institutions | 13.09% |
| Shares Short | 22.29K |
| Short % of Float | 0.28% |
| Short % of Shares Outstanding | 0.22% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:12 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -21.025% |
| Return on Equity (ttm) | -73.56% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -18855000 USD |
| Net Income Avi to Common (ttm) | -39818000 USD |
| Diluted EPS (ttm) | -4.63 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 33.98M USD |
| Total Cash Per Share (mrq) | 3.34 USD |
| Total Debt (mrq) | 235K USD |
| Total Debt/Equity (mrq) | 0.68 USD |
| Current Ratio (mrq) | 11.84 |
| Book Value Per Share (mrq) | 4.257 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -20636000 USD |
| Levered Free Cash Flow (ttm) | -11741500 USD |
Profile of Cocrystal Pharma
| Country | United States |
| State | WA |
| City | Bothell |
| Address | 19805 North Creek Parkway |
| ZIP | 98011 |
| Phone | 305 425 1780 |
| Website | https://www.cocrystalpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 12 |
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
Q&A For Cocrystal Pharma Stock
What is a current COCP stock price?
Cocrystal Pharma COCP stock price today per share is 1.42 USD.
How to purchase Cocrystal Pharma stock?
You can buy COCP shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cocrystal Pharma?
The stock symbol or ticker of Cocrystal Pharma is COCP.
Which industry does the Cocrystal Pharma company belong to?
The Cocrystal Pharma industry is Biotechnology.
How many shares does Cocrystal Pharma have in circulation?
The max supply of Cocrystal Pharma shares is 10.17M.
What is Cocrystal Pharma Price to Earnings Ratio (PE Ratio)?
Cocrystal Pharma PE Ratio is now.
What was Cocrystal Pharma earnings per share over the trailing 12 months (TTM)?
Cocrystal Pharma EPS is -1.72 USD over the trailing 12 months.
Which sector does the Cocrystal Pharma company belong to?
The Cocrystal Pharma sector is Healthcare.
Cocrystal Pharma COCP included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
| NASDAQ Capital Market Composite RCMP | 92.16 USD — |
-4.45
|
— — | 89.57 USD — | 93.85 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
- {{ link.label }} {{link}}